Cover Image
市場調查報告書

慢性阻塞性肺病(COPD)及氣喘治療器具的全球市場(產品種·各地區) - 市場規模,佔有率,全球趨勢,企業簡介,需求,考察,分析,調查,報告,機會,市場區隔及預測

Global COPD and Asthma Devices Market (Product Types and Geography) - Size, Share, Global Trends, Company Profiles, Demand, Insights, Analysis, Research, Report, Opportunities, Segmentation and Forecast, 2013 - 2020

出版商 Allied Market Research 商品編碼 320781
出版日期 內容資訊 英文 130 Pages
商品交期: 最快1-2個工作天內
價格
Back to Top
慢性阻塞性肺病(COPD)及氣喘治療器具的全球市場(產品種·各地區) - 市場規模,佔有率,全球趨勢,企業簡介,需求,考察,分析,調查,報告,機會,市場區隔及預測 Global COPD and Asthma Devices Market (Product Types and Geography) - Size, Share, Global Trends, Company Profiles, Demand, Insights, Analysis, Research, Report, Opportunities, Segmentation and Forecast, 2013 - 2020
出版日期: 2014年11月14日 內容資訊: 英文 130 Pages
簡介

慢性阻塞性肺病(COPD)及氣喘治療器具是全球呼吸疾病市場佔最大組合比例的領域,根據「氣喘管理相關國際指南(GINA)」的估計,全球約有3億氣喘患者,此外COPD更指出2013年死亡人數為300萬人佔死因第三名,該年以實際成果為準之治療器具市場規模相當於253億美金。

本報告以慢性阻塞性肺病(COPD)及氣喘治療器具的全球市場為焦點,依產品種及地區別分析·預測交易規模的轉變,更彙整市場發展的推動·阻礙因素,研究開發,競爭環境,主要加入企業等相關的最新資訊。

第1章 簡介

  • 報告內容
  • 調查實施的理由
  • 報告的主要優點
  • 主要市場區隔
  • 報告的推薦用戶層
  • 調查方法
    • 二次資訊調查
    • 一次資訊採訪
    • 分析工具及模式

第2章 摘要整理

  • 經營首腦的觀點
  • 市場預測(單位:100萬美元)
    • 穩定成長方案
    • 急速成長方案
    • 減速成長方案

第3章 市場概要

  • 市場定義和範圍
  • 重要發現
    • 慢性阻塞性肺病及氣喘器具全球市場的主要影響係數
    • 慢性阻塞性肺病及氣喘器具全球市場的有力資金來源
    • 慢性阻塞性肺病及氣喘器具全球市場的成功重要策略
  • 行政府法規
  • 波特的五力分析
  • 價值鏈分析
  • 臨床實驗
  • 專利分析
  • 市場佔有率分析
  • 市場動態
    • 推動要素
    • 阻礙因素
    • 機會

第4章 慢性阻塞性肺病及氣喘治療器具的全球市場 - 各產品種類(單位:100萬美元)

  • 吸入器(Inhalers)
    • 藥粉吸入器(DPI)
      • 重要市場趨勢
      • 重要成長係數及機會
      • 市場規模及預測
    • 定量噴霧吸入器(MDI)
    • 軟霧吸入器(SMI)
  • 噴霧器(Nebulizers)
    • 壓縮噴霧器
    • 超音波噴霧器
    • 網式噴霧器

第5章 慢性阻塞性肺病及氣喘治療器具的全球市場 - 各地區(單位:100萬美元)

  • 北美
    • 重要市場趨勢
    • 重要成長係數及機會
    • 市場規模及預測
    • 美國
    • 加拿大
    • 墨西哥
    • 其他
  • 歐洲
    • 重要市場趨勢
    • 重要成長係數及機會
    • 市場規模及預測
    • 法國
    • 德國
    • 英國
    • 其他
  • 亞太地區
    • 重要市場趨勢
    • 重要成長係數及機會
    • 市場規模及預測
    • 印度
    • 中國
    • 日本
    • 澳洲
    • 其他
  • 其他地區
    • 重要市場趨勢
    • 重要成長係數及機會
    • 市場規模及預測
    • 中南美
    • 中東
    • 非洲

第6章 企業簡介(企業概要,短評,收益,業務部門,策略性動向及發展,SWOT分析)

  • GlaxoSmithKline Plc
  • Novartis AG
  • Merck & Co., Inc.
  • Philips Healthcare
  • AstraZeneca Plc
  • 3M Health Care
  • Allied Healthcare Products Inc.
  • GF Health Products Inc.
  • Sunovion Pharmaceuticals Inc.
  • Smith Medicals
  • Lincare Holdings Inc.
  • Baxter International
目錄
Product Code: ME 14579

The COPD and Asthma hold the largest market share within the global respiratory diseases' market. As estimated by Global Initiative for Asthma (GINA), approximately 300 million people suffer from Asthma globally. COPD was the 3rd leading cause for death with 3 million people in 2013. Variety of drug-delivery methods such as oral and parenteral delivery have been deployed for treatment of COPD and Asthma; however, the pulmonary drug delivery system is the most effective drug-delivery technology as compared to the other (stated) conventional methods. The pulmonary drug delivery system includes devices such as inhalers and nebulizers - that are types of COPD and Asthma devices. Owing to all of the afore-mentioned factors the global COPD and Asthma devices' market was valued at $25.3 billion in 2013. The global COPD and Asthma devices market is segmented based on product/device types - inhalers and nebulizers. There are three types of inhalers, namely Dry Powder Inhalers (DPIs), Metered Dose Inhalers (MDIs) and Soft Mist Inhalers (SMIs). Currently, MDIs constitute to the largest market share of about 46% of the global COPD and Asthma devices market.

The DPIs is the fastest growing segment owing to the increase in the adoption rate of DPIs (as compared to other types of inhalers). The ability of DPIs to deliver small and large-sized drug molecules, as well as specialty engineered molecules render it to be the most preferred inhaler by the customers (doctors);therefore, contributing largely to the growth of the DPIs segment market. The other product type segment, i.e. the Nebulizers, is the device wherein the liquid formulation of drug is dispensed with the help of compressed air. There are various types of nebulizers developed and supplied such as Compressor Nebulizers, Ultrasonic Nebulizers and Mesh Nebulizers. The nebulizers hold a largest market share in the Home Healthcare application, as the product design of nebulizers offers benefits to debilitated patients, geriatrics and children.

Geographically, the COPD and Asthma devices market is segmented into North America, Europe, Asia-Pacific and LAMEA. North America holds the largest market share followed by Europe. Patent expiry of many brands (of inhalers) leads to increased development and supply of such devices by local market players in the Asia-Pacific market; also coupled with the increasing prevalence of the COPD and Asthma diseases in the Asia-Pacific region, the factors will render high market share for the Asia-Pacific region, by 2020. Some of the key market players included in the report are GlaxoSmithKline Plc, Novartis AG, Merck & Co., Inc., AstraZeneca Plc, Philips Healthcare, 3M Health Care, Allied Healthcare Products Inc., Sunovion Pharmaceuticals Inc., GF Healthcare Products, Smith Medicals, Lincare Holdings Inc., and Baxter International.KEY BENEFITS

Competitor analysis of the global COPD and Asthma devices market helps to understand strategies adopted by various companies for growth The projections in the report are made by analyzing the current market trends and future market potential for the period of 2013-2020 in terms of value Pin-point analysis of geographic segments helps to identify opportunities for growth within the global COPD and Asthma Devices market Comprehensive analysis of factors that drive and restrict growth of the COPD and Asthma devices market is provided. For example, rising prevalence of respiratory disorders would drive the COPD and Asthma devices market; however, environmental concerns are likely to be a restraint of the market Market conditions of global COPD and Asthma devices across all geographic regions are comprehensively analyzed. Development of technologically advanced products such as ultrasonic nebulizers and other automated nebulizers are tracked. Porter's Five Forces model gives an in-depth analysis of the bargaining power of buyers and suppliers, threats of new entrants and substitutes and competition amongst the key market players

MARKET SEGMENTATION

The COPD and Asthma devices market is segmented based on product types and geography.

MARKET BY PRODUCT TYPE

  • Inhalers
  • Drug powder inhalers (DPIs)
  • Metered Dose Inhalers (MDIs)
  • Soft Mist Inhalers (SMIs)
  • Nebulizers
  • Compressor nebulizers
  • Ultrasonic Nebulizers
  • Mesh Nebulizers

MARKET BY GEOGRAPHY

  • North America
    • U.S.
    • Canada
    • Mexico
    • Europe
    • Germany
    • France
    • U.K.
    • Others
  • Asia-Pacific
    • India
    • China
    • Japan
    • Australia
    • Others
  • LAMEA
    • Latin America
    • Middle east
    • Africa

Table of Contents

CHAPTER 1 INTRODUCTION

  • 1.1 Report Description
  • 1.2 Reason for doing the study
  • 1.3 Key Benefits
  • 1.4 Key Market Segments
  • 1.5 Key Audiences
  • 1.6 Research Methodology
    • 1.6.1 Secondary Research
    • 1.6.2 Primary Research
    • 1.6.3 Analyst tools and models

CHAPTER 2 EXECUTIVE SUMMARY

  • 2.1 CXO perspective
  • 2.2 Market beyond what to expect by 2025 ($Million)
    • 2.2.1 Moderate growth scenario
    • 2.2.2 Rapid growth scenario
    • 2.2.3 Diminishing growth scenario

CHAPTER 3 MARKET OVERVIEW

  • 3.1 Market Definition and Scope
  • 3.2 Key Findings
    • 3.2.1 Top Factors Impacting on global COPD and Asthma devices market
    • 3.2.2 Top Investment Pockets of global COPD and Asthma devices market
    • 3.2.3 Top winning strategies of global COPD and Asthma devices market
  • 3.3 Government Regulations
  • 3.4 Porter's Five force Analysis
  • 3.5 Value chain analysis
  • 3.6 Clinical Trials
  • 3.7 Patent Analysis
  • 3.8 Market Share Analysis, 2013
  • 3.9 Market Dynamics
    • 3.9.1 Drivers
    • 3.9.2 Restraints
    • 3.9.3 Opportunities

CHAPTER 4 GLOBAL COPD AND ASTHMA DEVICES MARKET BY PRODUCT TYPE, 2013-2020, $MILLION

  • 4.1 Inhalers
    • 4.1.1 Drug powder inhalers (DPIs)
      • 4.1.1.1 Key market trends
      • 4.1.1.2 Key growth factors and opportunities
      • 4.1.1.3 Market size and forecast
    • 4.1.2 Metered Dose Inhalers (MDIs)
      • 4.1.2.1 Key market trends
      • 4.1.2.2 Key growth factors and opportunities
      • 4.1.2.3 Market size and forecast
    • 4.1.3 Soft Mist Inhalers (SMIs)
      • 4.1.3.1 Key market trends
      • 4.1.3.2 Key growth factors and opportunities
      • 4.1.3.3 Market size and forecast
  • 4.2 Nebulizers
    • 4.2.1 Compressor Nebulizers
    • 4.2.2 Ultrasonic Nebulizers
    • 4.2.3 Mesh Nebulizers

CHAPTER 5 GLOBAL COPD AND ASTHMA DEVICES MARKET BY GEOGRAPHY, 2013-2020, $MILLION

  • 5.1 North America
    • 5.1.1 Key market trends
    • 5.1.2 Key growth factors and opportunities
    • 5.1.3 Market size and forecast
    • 5.1.4 United States
      • 5.1.4.1 Market size and forecast
    • 5.1.5 Canada
      • 5.1.5.1 Market size and forecast
    • 5.1.6 Mexico
      • 5.1.6.1 Market size and forecast
    • 5.1.7 Others
      • 5.1.7.1 Market size and forecast
  • 5.2 Europe
    • 5.2.1 Key market trends
    • 5.2.2 Key growth factors and opportunities
    • 5.2.3 Market size and forecast
    • 5.2.4 France
      • 5.2.4.1 Market size and forecast
    • 5.2.5 Germany
      • 5.2.5.1 Market size and forecast
    • 5.2.6 United Kingdom
      • 5.2.6.1 Market size and forecast
    • 5.2.7 Others
      • 5.2.7.1 Market size and forecast
  • 5.3 Asia-Pacific
    • 5.3.1 Key market trends
    • 5.3.2 Key growth factors and opportunities
    • 5.3.3 Market size and forecast
    • 5.3.4 India
      • 5.3.4.1 Market size and forecast
    • 5.3.5 China
      • 5.3.5.1 Market size and forecast
    • 5.3.6 Japan
      • 5.3.6.1 Market size and forecast
    • 5.3.7 Australia
      • 5.3.7.1 Market size and forecast
    • 5.3.8 Others
    • 5.3.8.1 Market size and forecast
  • 5.4 LAMEA
    • 5.4.1 Key market trends
    • 5.4.2 Key growth factors and opportunities
    • 5.4.3 Market size and forecast
    • 5.4.4 Latin America
      • 5.4.4.1 Market size and forecast
    • 5.4.5 Middle East
      • 6.4.5.1 Market size and forecast
    • 5.4.6 Africa
      • 5.4.6.1 Market size and forecast

CHAPTER 6 COMPANY PROFILES

  • 6.1 GlaxoSmithKline Plc
    • 6.1.1 Overview
    • 6.1.2 Company snapshot
    • 6.1.3 Financial performance
    • 6.1.4 Operating segment
    • 6.1.5 Strategic moves and developments
    • 6.1.6 SWOT analysis
  • 6.2 Novartis AG
    • 6.2.1 Overview
    • 6.2.2 Company snapshot
    • 6.2.3 Financial performance
    • 6.2.4 Operating segment
    • 6.2.5 Strategic moves and developments
    • 6.2.6 SWOT analysis
  • 6.3 Merck & Co., Inc.
    • 6.3.1 Overview
    • 6.3.2 Company snapshot
    • 6.3.3 Financial performance
    • 6.3.4 Operating segment
    • 6.3.5 Strategic moves and developments
    • 6.3.6 SWOT analysis
  • 6.4 Philips Healthcare
    • 6.4.1 Overview
    • 6.4.2 Company snapshot
    • 6.4.3 Financial performance
    • 6.4.4 Operating segment
    • 6.4.5 Strategic moves and developments
    • 6.4.6 SWOT analysis
  • 6.5 AstraZeneca Plc
    • 6.5.1 Overview
    • 6.5.2 Company snapshot
    • 6.5.3 Financial performance
    • 6.5.4 Operating segment
    • 6.5.5 Strategic moves and developments
    • 6.5.6 SWOT analysis
  • 6.6 3M Health Care
    • 6.6.1 Overview
    • 6.6.2 Company snapshot
    • 6.6.3 Financial performance
    • 6.6.4 Operating segment
    • 6.6.5 Strategic moves and developments
    • 6.6.6 SWOT analysis
  • 6.7 Allied Healthcare Products Inc.
    • 6.7.1 Overview
    • 6.7.2 Company snapshot
    • 6.7.3 Financial performance
    • 6.7.4 Operating segment
    • 6.7.5 Strategic moves and developments
    • 6.7.6 SWOT analysis
  • 6.8 GF Health Products Inc.
    • 6.8.1 Overview
    • 6.8.2 Company snapshot
    • 6.8.3 Financial performance
    • 6.8.4 Operating segment
    • 6.8.5 Strategic moves and developments
    • 6.8.6 SWOT analysis
  • 6.9 Sunovion Pharmaceuticals Inc.
    • 6.9.1 Overview
    • 6.9.2 Company snapshot
    • 6.9.3 Financial performance
    • 6.9.4 Operating segment
    • 6.9.5 Strategic moves and developments
    • 6.9.6 SWOT analysis
  • 6.10 Smith Medicals
    • 6.10.1 Overview
    • 6.10.2 Company snapshot
    • 6.10.3 Financial performance
    • 6.10.4 Operating segment
    • 6.10.5 Strategic moves and developments
    • 6.10.6 SWOT analysis
  • 6.11 Lincare Holdings Inc.
    • 6.11.1 Overview
    • 6.11.2 Company snapshot
    • 6.11.3 Financial performance
    • 6.11.4 Operating segment
    • 6.11.5 Strategic moves and developments
    • 6.11.6 SWOT analysis
  • 6.12 Baxter International
    • 6.12.1 Overview
    • 6.12.2 Company snapshot
    • 6.12.3 Financial performance
    • 6.12.4 Operating segment
    • 6.12.5 Strategic moves and developments
    • 6.12.6 SWOT analysis

List of Tables

  • TABLE. 1 TOP IMPACTING FACTOR, BASE CASE SCENARIO (2020-2025)
  • TABLE 2 TOP IMPACTING FACTOR OPTIMISTIC SCENARIO (2020-2025)
  • TABLE 3 TOP IMPACTING FACTOR CRITICAL SCENARIO (2020-2025)
  • TABLE 4 GLOBAL COPD AND ASTHMA DEVICES MARKET BY TYPES, 2013-2020, ($MILLION)
  • TABLE 5 GLOBAL COPD AND ASTHMA INHALERS MARKET BY TYPES, 2013-2020, ($MILLION)
  • TABLE 6 GLOBAL COPD AND ASTHMA INHALERS - DRY POWDER INHALERS MARKET BY GEOGRAPHY, 2013-2020, ($MILLION)
  • TABLE 7 GLOBAL COPD AND ASTHMA INHALERS - METERED DOSE INHALERS MARKET BY GEOGRAPHY, 2013-2020, ($MILLION)
  • TABLE 6 GLOBAL COPD AND ASTHMA INHALERS - SOFT MIST INHALERS MARKET BY GEOGRAPHY, 2013-2020, ($MILLION)
  • TABLE 9 GLOBAL COPD AND ASTHMA NEBULIZERS MARKET BY TYPES, 2013-2020, ($MILLION)
  • TABLE 10 GLOBAL COPD AND ASTHMA NEBULIZERS - COMPRESSOR NEBULIZERS MARKET BY GEOGRAPHY, 2013-2020, ($MILLION)
  • TABLE 11 GLOBAL COPD AND ASTHMA NEBULIZERS- ULTRASONIC NEBULIZERS MARKET BY GEOGRAPHY, 2013-2020, ($MILLION)
  • TABLE 12 GLOBAL COPD AND ASTHMA NEBULIZERS - MESH NEBULIZERS MARKET BY GEOGRAPHY, 2013-2020, ($MILLION)
  • TABLE 13 GLOBAL COPD AND ASTHMA DEVICES MARKET BY GEOGRAPHY, 2013-2020, ($MILLION)
  • TABLE 14 NORTH AMERICA COPD AND ASTHMA DEVICES MARKET BY TYPES, 2013-2020, ($MILLION)
  • TABLE 15 UNITED STATES COPD AND ASTHMA DEVICES MARKET BY TYPES, 2013-2020, ($MILLION)
  • TABLE 16 CANADA COPD AND ASTHMA DEVICES MARKET BY TYPES, 2013-2020, ($MILLION)
  • TABLE 17 MEXICO COPD AND ASTHMA DEVICES MARKET BY TYPES, 2013-2020, ($MILLION)
  • TABLE 18 OTHER NORTH AMERICA COPD AND ASTHMA DEVICES MARKET BY TYPES, 2013-2020, ($MILLION)
  • TABLE 19 EUROPE COPD AND ASTHMA DEVICES MARKET BY TYPES, 2013-2020, ($MILLION)
  • TABLE 20 GERMANY COPD AND ASTHMA DEVICES MARKET BY TYPES, 2013-2020, ($MILLION)
  • TABLE 21 FRANCE COPD AND ASTHMA DEVICES MARKET BY TYPES, 2013-2020, ($MILLION)
  • TABLE 22 UNITED KINGDOM COPD AND ASTHMA DEVICES MARKET BY TYPES, 2013-2020, ($MILLION)
  • TABLE 23 OTHER EUROPE COPD AND ASTHMA DEVICES MARKET BY TYPES, 2013-2020, ($MILLION)
  • TABLE 24 ASIA-PACIFIC COPD AND ASTHMA DEVICES MARKET BY TYPES, 2013-2020, ($MILLION)
  • TABLE 25 CHINA COPD AND ASTHMA DEVICES MARKET BY TYPES, 2013-2020, ($MILLION)
  • TABLE 26 INDIA COPD AND ASTHMA DEVICES MARKET BY TYPES, 2013-2020, ($MILLION)
  • TABLE 27 JAPAN COPD AND ASTHMA DEVICES MARKET BY TYPES, 2013-2020, ($MILLION)
  • TABLE 28 AUSTRALIA COPD AND ASTHMA DEVICES MARKET BY TYPES, 2013-2020, ($MILLION)
  • TABLE 29 OTHER ASIA-PACIFIC COPD AND ASTHMA DEVICES MARKET BY TYPES, 2013-2020, ($MILLION)
  • TABLE 30 LAMEA COPD AND ASTHMA DEVICES MARKET BY TYPES, 2013-2020, ($MILLION)
  • TABLE 31 LATIN AMERICA COPD AND ASTHMA DEVICES MARKET BY TYPES, 2013-2020, ($MILLION)
  • TABLE 32 MIDDLE EAST COPD AND ASTHMA DEVICES MARKET BY TYPES, 2013-2020, ($MILLION)
  • TABLE 33 AFRICA COPD AND ASTHMA DEVICES MARKET BY TYPES, 2013-2020, ($MILLION)
  • TABLE 34 GLAXOSMITHKLINE PLC BUSINESS SNAPSHOT
  • TABLE 35 GLAXOSMITHKLINE PLC OPERATING SEGMENTS
  • TABLE 36 NOVARTIS AG BUSINESS SNAPSHOT
  • TABLE 37 NOVARTIS AG OPERATING SEGMENTS
  • TABLE 38 MERCK AND CO BUSINESS SNAPSHOT
  • TABLE 39 MERCK AND CO OPERATING SEGMENTS
  • TABLE 40 ASTRAZENECA PLC BUSINESS SNAPSHOT
  • TABLE 41 ASTRAZENECA PLC OPERATING SEGMENTS
  • TABLE 42 PHILIPS HEALTHCARE BUSINESS SNAPSHOT
  • TABLE 43 PHILIPS HEALTHCARE OPERATING SEGMENTS
  • TABLE 44 3M HEALTH CARE BUSINESS SNAPSHOT
  • TABLE 45 3M HEALTH CARE OPERATING SEGMENTS
  • TABLE 46 ALLIED HEALTHCARE PRODUCTS INC BUSINESS SNAPSHOT
  • TABLE 47 ALLIED HEALTHCARE PRODUCTS INC OPERATING SEGMENTS
  • TABLE 48 SUNOVION PHARMACEUTICALS BUSINESS SNAPSHOT
  • TABLE 49 SUNOVION PHARMACEUTICALS OPERATING SEGMENTS
  • TABLE 50 GF HEALTH PRODUCTS BUSINESS SNAPSHOT
  • TABLE 51 GF HEALTH PRODUCTS OPERATING SEGMENTS
  • TABLE 52 SMITH MEDICALS BUSINESS SNAPSHOT
  • TABLE 53 SMITH MEDICALS OPERATING SEGMENTS
  • TABLE 54 LINCARE HOLDINGS INC BUSINESS SNAPSHOT
  • TABLE 55 LINCARE HOLDINGS INC OPERATING SEGMENTS
  • TABLE 56 BAXTER INTERNATIONAL BUSINESS SNAPSHOT
  • TABLE 57 BAXTER INTERNATIONAL OPERATING SEGMENTS

List of Figures

  • FIG. 1 TOP IMPACTING FACTOR, BASE CASE SCENAIRIO (2020-2025)
  • FIG. 2 TOP IMPACTING FACTOR OPTEMISTIC SCENAIRIO (2020-2025)
  • FIG. 3 TOP IMPACTING FACTOR CRITICAL SCENAIRIO (2020-2025)
  • FIG 4 TOP FACTORS IMPACTING GLOBAL COPD AND ASTHMA DEVICES MARKET, 2013
  • FIG. 5 TOP WINNING STRATEGY IN CLOBAL COPD AND ASTHMA DEVICES MARKET, 2010 TO 2014
  • FIG. 6 TOP INVESTMENT POCKETS IN GLOBAL COPD AND ASTHMA DEVICES MARKETS (2013)
  • FIG. 7 PORTER FIVE FORCES ANALYSIS OF GLOBAL COPD AND ASTHMA DEVICES MARKETS
  • FIG. 8 VALUE CHAIN ANALYSIS OF GLOBAL COPD AND ASTHMA DEVICES MARKETS
  • FIG. 9 PATENT ANALYSIS IN GLOBAL COPD AND ASTHMA DEVICES MARKET, 2010-2014
  • FIG. 10 MARKET SHARE ANALYSIS OF COPD AND ASTHMA DEVICES MARKET (2013)
  • FIG. 11 RECENT DEVELOPMENTS OF GLOBAL COPD AND ASTHMA DEVICES MARKET (2010-2014)
  • FIG. 12 GLAXOSMITHKLINE PLC SWOT ANALYSIS
  • FIG. 13 NOVARTIS AG SWOT ANALYSIS
  • FIG. 14 MERCK AND CO., INC SWOT ANALYSIS
  • FIG. 15 ASTRAZENECA PLC SWOT ANALYSIS
  • FIG. 16 PHILIPS HEALTHCARE SWOT ANALYSIS
  • FIG. 17 3M HEALTH CARE SWOT ANALYSIS
  • FIG. 18 ALLIED HEALTHCARE PRODUCTS INC SWOT ANALYSIS
  • FIG. 19 SUNOVION PHARMACEUTICALS INC SWOT ANALYSIS
  • FIG. 20 GF HEALTH PRODUCTS SWOT ANALYSIS
  • FIG. 21 SMITH MEDICALS SWOT ANALYSIS
  • FIG. 22 LINCARE HOLDINGS INC SWOT ANALYSIS
  • FIG. 23 BAXTER INTERNATIONAL SWOT ANALYSIS
Back to Top